BHCM
OPRX icon

Brevan Howard Capital Management’s OptimizeRx OPRX Stock Holding History

Brevan Howard Capital Management’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,626
Closed -$281K – 1261
2023
Q4 		$281K Buy
19,626
+4,001
+26% +$38.4K ﹤0.01% 745
2023
Q3 		$122K Hold
15,625
– – ﹤0.01% 345
2023
Q2 		$223K Hold
15,625
– – ﹤0.01% 174
2023
Q1 		$229K Buy
+15,625
New +$261K 0.01% 113

Other funds holding OPRX

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $4.41B AUM 90.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
SM
Samjo Management New York $293M AUM 57.03% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return

Brevan Howard Capital Management's OPRX Position: Q1 2024 in Review

Brevan Howard Capital Management sold out of OptimizeRx (OPRX) in Q1 2024, closing a stake of 19,626 shares — an estimated $281K sold.

Brevan Howard Capital Management first reported a position in OPRX in Q1 2023 and held it in 4 quarters. The position peaked at $281K in Q4 2023. 97 funds tracked by Wall St. Rank hold OPRX as of Q1 2024.

  • Brevan Howard Capital Management reported no remaining OptimizeRx position as of Q1 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 19,626 OptimizeRx shares in Q1 2024, an estimated $281K.
  • Brevan Howard Capital Management first reported a position in OptimizeRx in Q1 2023 and held it in 4 quarters.
  • Brevan Howard Capital Management's OptimizeRx position peaked at $281K in Q4 2023.
  • 97 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2024.

Based on Brevan Howard Capital Management's 13F filing for Q1 2024, filed 15 May 2024.